This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Hologic Yönetim
Yönetim kriter kontrolleri 4/4
Hologic CEO'su Steve MacMillan, Dec2013 tarihinde atandı, in görev süresi 12.33 yıldır. in toplam yıllık tazminatı $ 15.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.9% maaş ve 92.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.57% ine doğrudan sahiptir ve bu hisseler $ 96.93M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 7.4 yıldır.
Anahtar bilgiler
Steve MacMillan
İcra Kurulu Başkanı
US$15.9m
Toplam tazminat
| CEO maaş yüzdesi | 7.88% |
| CEO görev süresi | 12.3yrs |
| CEO sahipliği | 0.6% |
| Yönetim ortalama görev süresi | 2.5yrs |
| Yönetim Kurulu ortalama görev süresi | 7.4yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Apr 10
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading
Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.Anlatı Güncellemesi • Mar 26
HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes
Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.Anlatı Güncellemesi • Mar 12
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes
Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.Anlatı Güncellemesi • Feb 26
HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path
Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.Anlatı Güncellemesi • Feb 11
HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026
Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.Anlatı Güncellemesi • Jan 26
HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026
Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.Anlatı Güncellemesi • Jan 12
HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026
Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.Anlatı Güncellemesi • Dec 18
HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026
We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.Anlatı Güncellemesi • Dec 04
HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026
The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.Anlatı Güncellemesi • Nov 20
HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026
Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.Anlatı Güncellemesi • Nov 05
HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance
Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.Anlatı Güncellemesi • Oct 22
Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum
Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.Anlatı Güncellemesi • Sep 28
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.Analiz Makalesi • Sep 13
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Anlatı Güncellemesi • Sep 05
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.Analiz Makalesi • Aug 04
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report
Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...Analiz Makalesi • Jul 19
Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...Analiz Makalesi • Jul 01
The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)
With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...Analiz Makalesi • Jun 13
Is Hologic (NASDAQ:HOLX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 06
Hologic: Soft Performance, But Cheap Enough
Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
Hologic: Reasonably, But Not Compellingly Valued
Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Hologic: Continued Room Amidst Bolt-On M&A Efforts
Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them
Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Dec 27 2025 | n/a | n/a | US$544m |
| Sep 27 2025 | US$16m | US$1m | US$566m |
| Jun 28 2025 | n/a | n/a | US$557m |
| Mar 29 2025 | n/a | n/a | US$557m |
| Dec 28 2024 | n/a | n/a | US$744m |
| Sep 28 2024 | US$16m | US$1m | US$790m |
| Jun 29 2024 | n/a | n/a | US$702m |
| Mar 30 2024 | n/a | n/a | US$467m |
| Dec 30 2023 | n/a | n/a | US$515m |
| Sep 30 2023 | US$16m | US$1m | US$456m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$753m |
| Dec 31 2022 | n/a | n/a | US$990m |
| Sep 24 2022 | US$14m | US$1m | US$1b |
| Jun 25 2022 | n/a | n/a | US$2b |
| Mar 26 2022 | n/a | n/a | US$2b |
| Dec 25 2021 | n/a | n/a | US$2b |
| Sep 25 2021 | US$15m | US$1m | US$2b |
| Jun 26 2021 | n/a | n/a | US$2b |
| Mar 27 2021 | n/a | n/a | US$2b |
| Dec 26 2020 | n/a | n/a | US$1b |
| Sep 26 2020 | US$14m | US$1m | US$1b |
| Jun 27 2020 | n/a | n/a | US$497m |
| Mar 28 2020 | n/a | n/a | US$453m |
| Dec 28 2019 | n/a | n/a | US$84m |
| Sep 28 2019 | US$12m | US$1m | -US$204m |
Tazminat ve Piyasa: Steve 'ın toplam tazminatı ($USD 15.93M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 14.80M ).
Tazminat ve Kazançlar: Steve 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Steve MacMillan (61 yo)
12.3yrs
Görev süresi
US$15,931,655
Tazminat
Mr. Stephen P. MacMillan, also known as Steve, serves as a Director of EZ LIFT Rescue Systems, Inc. and Business Leaders for Michigan. He served as an Independent Chairman of the Board at Illumina, Inc. fr...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$15.93m | 0.57% $ 96.9m | |
| Chief Financial Officer | 7.7yrs | US$4.39m | 0.025% $ 4.3m | |
| Chief Operating Officer | 2.3yrs | US$5.08m | 0.0091% $ 1.5m | |
| Group President of International | no data | US$3.46m | 0.050% $ 8.4m | |
| President of Diagnostic Solutions | 3yrs | US$3.13m | 0.0026% $ 440.8k | |
| Chief Information Officer | 4.8yrs | Veri yok | Veri yok | |
| Corporate Vice President of Investor Relations | 1.3yrs | Veri yok | Veri yok | |
| General Counsel | less than a year | Veri yok | 0.013% $ 2.1m | |
| Senior Vice President of Global Human Resources | 1.7yrs | Veri yok | 0.0034% $ 575.9k | |
| VP & Chief of Staff | 12.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Global Supply Chain & Regulatory Affairs | 2.5yrs | Veri yok | Veri yok | |
| President of GYN Surgical Solutions | 2.3yrs | Veri yok | 0.0078% $ 1.3m |
2.5yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: HOLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$15.93m | 0.57% $ 96.9m | |
| Independent Director | 1.3yrs | US$355.90k | 0.0034% $ 579.3k | |
| Independent Director | 3.3yrs | US$329.97k | 0.00078% $ 131.7k | |
| Independent Director | 7.4yrs | US$329.97k | 0.0042% $ 700.9k | |
| Independent Director | 8.9yrs | US$354.97k | 0.0084% $ 1.4m | |
| Independent Director | 1yr | US$258.46k | 0.00078% $ 131.7k | |
| Independent Director | 14.4yrs | US$329.97k | 0.021% $ 3.6m | |
| Lead Independent Director | 9.3yrs | US$384.97k | 0.0093% $ 1.6m | |
| Independent Director | 2.6yrs | US$344.97k | 0.0019% $ 315.8k |
7.4yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HOLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.4 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/04/06 14:21 |
| Gün Sonu Hisse Fiyatı | 2026/04/06 00:00 |
| Kazançlar | 2025/12/27 |
| Yıllık Kazançlar | 2025/09/27 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Hologic, Inc. 25 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |